Clinical Trial Update: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating rituximab for adult acquired idiopathic thrombotic thrombocytopenic purpura.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Thrombotic Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED